PYC Therapeutics Valuation
| PYC Stock | 1.40 0.05 3.45% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. PYC Therapeutics owns a latest Real Value of USD1.31 per share. The recent price of the company is USD1.4. Our model determines the value of PYC Therapeutics from examining the company fundamentals such as return on asset of -0.38, and Operating Margin of (1.78) % as well as analyzing its technical indicators and probability of bankruptcy.
Price Book 8.1154 | Enterprise Value 587.5 M | Enterprise Value Ebitda (8.41) | Price Sales 29.6134 |
Overvalued
Today
Please note that PYC Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of PYC Therapeutics is based on 3 months time horizon. Increasing PYC Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
PYC Therapeutics' intrinsic value may or may not be the same as its current market price of 1.40, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.4 | Real 1.31 | Hype 1.4 |
The intrinsic value of PYC Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence PYC Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of PYC Therapeutics helps investors to forecast how PYC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PYC Therapeutics more accurately as focusing exclusively on PYC Therapeutics' fundamentals will not take into account other important factors: PYC Therapeutics Cash |
|
PYC Therapeutics Total Value Analysis
PYC Therapeutics is at this time forecasted to have takeover price of 587.49 M with market capitalization of 653.25 M, debt of 1.11 M, and cash on hands of 15.57 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the PYC Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
587.49 M | 653.25 M | 1.11 M | 15.57 M |
PYC Therapeutics Investor Information
About 59.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.1. PYC Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 15th of November 2024. Based on the key indicators related to PYC Therapeutics' liquidity, profitability, solvency, and operating efficiency, PYC Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.PYC Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. PYC Therapeutics has an asset utilization ratio of 24.18 percent. This implies that the Company is making USD0.24 for each dollar of assets. An increasing asset utilization means that PYC Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.PYC Therapeutics Ownership Allocation
PYC Therapeutics secures a total of 466.61 Million outstanding shares. PYC Therapeutics shows noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.PYC Therapeutics Profitability Analysis
The company reported the revenue of 22.06 M. Net Loss for the year was (37.73 M) with profit before overhead, payroll, taxes, and interest of 15.81 M.About PYC Therapeutics Valuation
The stock valuation mechanism determines PYC Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of PYC Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of PYC Therapeutics. We calculate exposure to PYC Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PYC Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 22.1 M | 23.2 M |
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.